Recent Publications

• A digital protein microarray for COVID-19 cytokine storm monitoring. Lab Chip. 2020 Nov 19.

• Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non-Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases. Ann Pharmacother. 2020 Oct 17;1060028020967629.

• Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma. J Clin Invest. 2020 Oct 1;130(10):5313-5325.

• Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura. J Oncol Pharm Pract. 2020 Oct;26(7):1695-1702.

• Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020 Jul 11;ciaa954.

• Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas. Leuk Lymphoma. 2020 May;61(5):1126-1132.

• Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. Crit Rev Oncol Hematol. 2020 Apr;148:102897.

• Trends in the delivery of care to oncology patients in the United States: Emphasis on the role pharmacists on the healthcare team. J Oncol Pharm Pract. 2020 Apr 1;1078155220907674.

• Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy. J Oncol Pharm Pract. 2020 Apr;26(3):564-571.

• Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosis. 2020 Apr;61(4):862-868.

• Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2020 Mar;61(3):691-698.

• Cost considerations in the first-line treatment of advanced Hodgkin lymphoma. Lancet Haematol. 2020 Feb;7(2):e91-e93.

• Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma. Curr Oncol Rep. 2020 Feb 6;22(2):19.

• Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM. Clin Lymphoma Myeloma Leuk . 2020 Jan;20(1):24-30.

• Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia. Blood Adv. 2019 Nov 12;3(21):3333-3336.

• Dosing Vincristine in Dose-Adjusted EPOCH-R: To Cap or Not to Cap? J Clin Oncol. 2019 Nov 1;37(31):2952.​

• Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma. J Oncol Pharm Pract. 2019 Nov 25:1078155219890023.

• Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations. Pharmacotherapy. 2019 Nov;39(11):1105-1112.

• A comparison of response in the presence or absence of a delay in induction therapy with bortezomib, lenalidomide, and dexamethasone. J Oncol Pharm Pract. 2019 Oct;25(7):1692-1698.

• Multicenter evaluation of arsenic trioxide dosing in obese patients with low-intermediate risk acute promyelocytic leukemia. Leuk Lymphoma. 2019 Jul 11:1-4.

• Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope? Cancer. 2019 Jul 10.

• Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents. Drugs. 2019 Jun;79(8):833-853.

• Irinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies. J Oncol Pharm Pract. 2019 Jun;25(4):980-986.

• Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Crit Rev Oncol Hematol. 2019 Sep;141:125-138.

• Clinician Report of Oral Oncolytic Symptoms and Adherence Obtained via a Patient-Reported Outcome Measure (PROM). JCO Clin Cancer Inform. 2019 May;3:1-6.

• A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. Leuk Lymphoma. 2019 May 17:1-15.​

• Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy, Open Forum Infectious Diseases, Volume 6, Issue 5, May 2019.​

• PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma. Lancet Oncol. 2019 Apr;20(4):e188.

• Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma. Invest New Drugs. 2019 Apr;37(2):323-330.

• Risk factors for cefepime nonsusceptible Gram-negative infections in allogeneic hematopoietic cell transplant recipients. J Oncol Pharm Pract. 2019 Mar;25(2):279-288.

• Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. Bone Marrow Transplant. 2019 Feb 26.

• Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol. 2019 Feb 26.

• Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction. J Oncol Pharm Pract. 2019 Feb 13:1078155219829534.

• Surface contamination of counting tools after mock dispensing of cyclophosphamide in a simulated outpatient pharmacy. J Oncol Pharm Pract. 2019 Jan;25(1):85-93.

• A comparison of response in the presence or absence of a delay in induction therapy with bortezomib, lenalidomide, and dexamethasone. J Oncol Pharm Pract. 2019 Oct;25(7):1692-1698.

• A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. J Oncol Pharm Pract. 2018 Sep;24(6):453-467.

• Impact of a Statewide Oral Oncolytic Initiative on Five Participating Practices. J Oncol Pract. 2018 May;14(5):e304-e309.

• The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Ann Hematol. 2019 Mar;98(3):541-559.

• Managing liver dysfunction in haematology patients: Switch antifungals, or use the tincture of time? Mycoses. 2019 Mar;62(3):214-216.

• Mothers in academic pharmacy. Curr Pharm Teach Learn. 2018 Sep;10(9):1168-1170.

• Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018 Aug;59(8):1797-1806.

• Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program. JCO Precis Oncol. 2018;2:PO.18.00011. doi: 10.1200/po.18.00011. Epub 2018 Jul 23.

• ​The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. Leuk Res. 2018 Jun 1;70:91-96.

• Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics. J Oncol Pract. 2018 Jun;14(6):e368-e374.

• Oncology Pharmacist Opportunities: Closing the Gap in Quality Care. J Oncol Pract. 2018 Jun;14(6):e403-e411.

• Impact of a Statewide Oral Oncolytic Initiative on Five Participating Practices. J Oncol Pract. 2018 May;14(5):e304-e309.

• Making Improvements in the ED: Does ED Busyness Affect Time to Antibiotics in Febrile Pediatric Oncology Patients Presenting to the Emergency Department? Pediatr Emerg Care. 2018 May;34(5):310-316.

• Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. Ann Hematol. 2018 Apr;97(4):573-584.

• Rational use of rasburicase for the treatment and management of tumor lysis syndrome. J Oncol Pharm Pract. 2018 Apr;24(3):176-184.

• PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018 Mar;59(3):617-624.

• Surface contamination of hazardous drug pharmacy storage bins and pharmacy distributor shipping containers. J Oncol Pharm Pract. 2018 Mar;24(2):91-97.

• Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology. J Neurooncol. 2018 Mar;137(1):155-169.

• Hematologic Manifestations of Deficiency of Adenosine Deaminase 2 (DADA2) and Response to Tumor Necrosis Factor Inhibition in DADA2-Associated Bone Marrow Failure. J Clin Immunol. 2018 Feb;38(2):166-173.

• Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report. J Oncol Pharm Pract. 2018 Jan 1:1078155217754244.

• Bone marrow edema associated with everolimus. Am J Health Syst Pharm. 2018 Jan 1;75(1):e23-e27.

• Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome. J Oncol Pharm Pract. 2018 Jan;24(1):67-73.

• Real-Life Challenges to the Use of Antifungal Agents in Hematology Patients. Curr Fungal Infect Rep (2017) 11: 229. https://doi.org/10.1007/s12281-017-0303-8

• Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment. Leuk Res. 2017 Dec;63:56-61.

• Comparison of Weight-Based Dosing Strategies for Intravenous Immunoglobulin in Patients with Hematologic Malignancies. Pharmacotherapy. 2017 Dec;37(12):1530-1536.

• Daptomycin nonsusceptible vancomycin resistant Enterococcus bloodstream infections in patients with hematological malignancies: risk factors and outcomes. Leuk Lymphoma. 2017 Dec;58(12):2852-2858.

• Comparison of Weight-Based Dosing Strategies for Intravenous Immunoglobulin in Patients with Hematologic Malignancies. Pharmacotherapy. 2017 Dec;37(12):1530-1536.

• Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Dec;15(12):1520-1541.

• Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma. Leuk Lymphoma. 2017 Nov 6:1-10. ​

• Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia. J Oncol Pharm Pract. 2017 Oct;23(7):502-517.

• Risk factors for subtherapeutic levels of posaconazole tablet. J Antimicrob Chemother. 2017 Oct 1;72(10):2902-2905.

• Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU. Pediatr Blood Cancer. 2017 Oct;64(10).

• Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. Transl Res. 2017 Oct;188:27.e1-27.e14.

• Catalyzing improvements in ALL therapy with asparaginase. Blood Rev. 2017 Sep;31(5):328-338.

• Identification and targeting of an FGFR fusion in a pediatric thalamic "central oligodendroglioma". NPJ Precis Oncol. 2017 Sep 7;1(1):29.

• mTOR regulates metabolic adaptation of APCs in the lung and controls the outcome of allergic inflammation. Science. 2017 Sep 8;357(6355):1014-1021.

• Clofarabine Dosing in a Patient With Acute Myeloid Leukemia on Intermittent Hemodialysis: Case Report and Review of the Literature. J Pediatr Hematol Oncol. 2017 Aug;39(6):481-484.

• Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation. J Antimicrob Chemother. 2017 Aug 1;72(8):2355-2358.

• Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant. J Oncol Pharm Pract. 2017 Jun;23(4):255-263.

• Risk factors and impact of Clostridium difficile recurrence on haematology patients. J Antimicrob Chemother. 2017 May 1;72(5):1488-1495.

• Implementing a Method for Evaluating Patient-Reported Outcomes Associated With Oral Oncolytic Therapy. J Oncol Pract. 2017 Apr;13(4):e395-e400.

• Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse/refractory acute myeloid leukemia. Support Care Cancer. 2017 Feb;25(2):541-547.

• Benefits of a concentrated teaching rotation: Perspectives of pharmacy residents and faculty. Curr Pharm Teach Learn. 2017 Jan - Feb;9(1):4-8.

• Cockcroft-Gault revisited: New de-liver-ance on recommendations for use in cirrhosis. World J Hepatol. 2017 Jan 28;9(3):131-138.

• Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction. J Oncol Pharm Pract. 2016 Dec;22(6):811-815.

• Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am J Cancer Res. 2016 Nov 1;6(11):2416-2430.

• Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget. 2016 Oct 4;7(40):65696-65706.

• Central Nervous System Complications of Hematopoietic Stem Cell Transplant. Hematol Oncol Clin North Am. 2016 Aug;30(4):887-98.

• Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor. Onco Targets Ther. 2016 May 10;9:2783-93.

• Perioperative Laboratory Abnormalities in Gynecologic Oncology Surgical Patients. J Gynecol Surg. 2016 Apr 1;32(2):111-118.

• Minimizing waste during preparation of blinatumomab infusions. Am J Health Syst Pharm. 2016 Jan 15;73(2):19-20.

• Evaluation of outpatient medication reconciliation involving student pharmacists at a comprehensive cancer center. J Am Pharm Assoc (2003). 2015 Sep-Oct;55(5):540-5.

• Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia. Support Care Cancer. 2015 Aug;23(8):2287-95.

• Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. Mycoses. 2015 Jul;58(7):432-6.

• Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy. Pediatr Blood Cancer. 2015 Jun;62(6):1115.

• Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Ann Hematol. 2015 Jun;94(6):1033-41.

• Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2015 May;21(5):809-20.

• Characterizing human herpes virus 6 following hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2015 Apr;21(2):85-92.

• Baseline body mass index among children and adults undergoing allogeneic hematopoietic cell transplantation: clinical characteristics and outcomes. Bone Marrow Transplant. 2015 Mar;50(3):402-10.

• Risk factors for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2014 Oct;16(5):744-50.

• Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant. 2014 Sep;20(9):1407-17.

• The effects of an informational video on patient knowledge, satisfaction and compliance with venous thromboembolism prophylaxis: a pilot study. Patient Educ Couns. 2014 Aug;96(2):264-7.

• Risk for invasive fungal infections during acute myeloid leukemia induction therapy: a true association with echinocandins? Antimicrob Agents Chemother. 2014 Aug;58(8):4988-9.

• Procarbazine and antidepressants: a retrospective review of the risk of serotonin toxicity. Psychooncology. 2014 Jan;23(1):108-13.

• The role of trastuzumab in the management of salivary ductal carcinomas. Anticancer Res. 2013 Jun;33(6):2587-91.

• Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemother. 2012 Dec;67(12):2957-62.

• Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2012 Nov 1;10(11):1412-45.

• Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. Anticancer Res. 2012 Jul;32(7):2391-8.

• Successful use of fondaparinux for bridging early after aortic and mitral mechanical heart valve replacement. Ann Pharmacother. 2012 Mar;46(3):e9.

• Stability of an extemporaneously prepared thalidomide suspension. Am J Health Syst Pharm. 2012 Jan 1;69(1):56-8.

• Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Support Care Cancer. 2011 Dec;19(12):1969-74.

• Isolated positive catheter cultures in the intensive care unit: what is the clinical significance? Crit Care Med. 2011 Nov;39(11):2586-7.

• Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood. 2011 Oct 13;118(15):4258-64.

• Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann Pharmacother. 2010 Oct;44(10):1633-40.

• Best practice management of CINV in oncology patients: I. Physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches. J Support Oncol. 2010 Mar-Apr;8(2 Suppl 1):5-9.